- Home
- CLSD vs AYTU Comparison
CLSD vs AYTU Comparison
Compare CLSD & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- AYTU
- Stock Information
- Founded
- CLSD 2011
- AYTU N/A
- Country
- CLSD United States
- AYTU United States
- Employees
- CLSD N/A
- AYTU N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CLSD Health Care
- AYTU Health Care
- Exchange
- CLSD Nasdaq
- AYTU Nasdaq
- Market Cap
- CLSD 20.4M
- AYTU 23.0M
- IPO Year
- CLSD 2016
- AYTU N/A
- Fundamental
- Price
- CLSD $2.75
- AYTU $2.03
- Analyst Decision
- CLSD Hold
- AYTU Strong Buy
- Analyst Count
- CLSD 4
- AYTU 3
- Target Price
- CLSD $75.00
- AYTU $9.17
- AVG Volume (30 Days)
- CLSD 42.9K
- AYTU 66.3K
- Earning Date
- CLSD 11-14-2025
- AYTU 11-13-2025
- Dividend Yield
- CLSD N/A
- AYTU N/A
- EPS Growth
- CLSD N/A
- AYTU N/A
- EPS
- CLSD N/A
- AYTU N/A
- Revenue
- CLSD $3,329,000.00
- AYTU $63,696,000.00
- Revenue This Year
- CLSD $98.20
- AYTU N/A
- Revenue Next Year
- CLSD $213.77
- AYTU $29.12
- P/E Ratio
- CLSD N/A
- AYTU N/A
- Revenue Growth
- CLSD N/A
- AYTU N/A
- 52 Week Low
- CLSD $2.54
- AYTU $0.95
- 52 Week High
- CLSD $17.10
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- CLSD 33.87
- AYTU 47.93
- Support Level
- CLSD $2.54
- AYTU $1.91
- Resistance Level
- CLSD $4.00
- AYTU $2.10
- Average True Range (ATR)
- CLSD 0.34
- AYTU 0.15
- MACD
- CLSD -0.16
- AYTU -0.01
- Stochastic Oscillator
- CLSD 10.47
- AYTU 58.00
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.